Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Aphria Inc. APHA

Aphria, which is headquartered in Ontario, produces and sells medicinal and recreational cannabis. The company operates through retail and wholesale channels in Canada and internationally. Aphria is a main distributor of medical cannabis to Germany and has operations in over 10 countries outside of Canada. However, it does not have exposure to the U.S. CBD or THC markets due to the constraints of federal prohibition. It has some U.S. exposure through the acquisition of SweetWater, a craft brewer


NDAQ:APHA - Post by User

Bullboard Posts
Comment by greenupon Oct 18, 2019 9:55am
44 Views
Post# 30243460

RE:RE:RE:RE:RE:A video worth watching

RE:RE:RE:RE:RE:A video worth watchingFirst of all thanks to original poster that posted this video, secondly, couldn't agree more with Peter. My neighbor's dog has seen more action than this juvenile lol what a joke. Finally, I sense the industry in general doesn't like Simon. Gl longs, I will be sending some more emails.
PeterMacd2 wrote: The young punk being interviewed here, Shayne Laidlaw, has been an "analyst "at Hedgeye for only 4 years, has never run a business, nor has he had much life experience worth mentioning:: https://www.wealthminder.com/financial-advisors-stamford-CT/ hayne-laidlaw/363370. So why is he given bandwidth to spread his ignorance? I just had to burst out laughing when he said at the end that he thinks APHA is a candidate for bankruptcy in the next year or two!  With half a billion in cash, and profitable?!  Clearly, as he said, he "dislikes" Irwin Simon. Oh, but Canopy is not going bust because they have 1 billion in the bank. And CRON is a winner because of CBD - obviously forgetting about APHA's ECoE coming online soon. Contemptible. 

"Analysts", to me, are like a school of fish. Ever seen a school of fish?  - they turn this way, that way, and back again, always in lock-step, you can't know what guides their movement, it's just how they aimlessly spend their time. But if you're interested in analysts' opinions, 9 out of 12 still rate APHA a buy with a median 12 month forecast of CAD $14. (range $7-$26). 
https://ca.investing.com/equities/aphria-inc-consensus-estimates. Personally, my 3 year estimate is $30 ($25-35); this assumes Diamond and the ECoC come online this quarter, and the EU business takes off as I think it will. JMO.




Bullboard Posts